Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON26050
NL-OMON26050
Not yet recruiting
Not Applicable

Botulinum Neurotoxin (BoNT) as new treatment for functional (psychogenic) jerky movementdisorders.

Academic Medical Center University of AmsterdamPO-box: 226601100 DD AmsterdamTel: 0031 (0)20 56691110 sites54 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsBotulinum neurotoxin (BoNT) has emerged as a useful therapy for several movement disorders associated with muscle overactivity such as dystonia and jerky movement disorders. At least 2–9% of patients seen in movement disorder clinics suffer from movement disorders with a psychogenic origin and a substantial part of them has jerks. These psychogenic jerky movement disorders cannot be accounted for by a known neurologic syndrome.

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Botulinum neurotoxin (BoNT) has emerged as a useful therapy for several movement disorders associated with muscle overactivity such as dystonia and jerky movement disorders. At least 2–9% of patients seen in movement disorder clinics suffer from movement disorders with a psychogenic origin and a substantial part of them has jerks. These psychogenic jerky movement disorders cannot be accounted for by a known neurologic syndrome.
Sponsor
Academic Medical Center University of AmsterdamPO-box: 226601100 DD AmsterdamTel: 0031 (0)20 5669111
Enrollment
54
Status
Not yet recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

/A

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Academic Medical Center University of AmsterdamPO-box: 226601100 DD AmsterdamTel: 0031 (0)20 5669111

Eligibility Criteria

Inclusion Criteria

  • •Patients with at least one invalidating consistent type of psychogenic jerk that is present for 1 year or longer.
  • •Patients with one consistent type of invalidating tremor present for one year or longer .

Exclusion Criteria

  • •1\. Age \< 18 years or \> 80 years;
  • •2\. Psychogenic jerk of interest present for \< 1 year;

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
Botuline toxine als nieuwe behandeling voor onverklaarde schokken.psychogenic movement disorder
NL-OMON28532Academic Medical CentreMeibergdreef 91105 AZ Amsterdam54
Recruiting
Not Applicable
botulinum in childhood strabismusEye DiseasesSurgeryPaediatricschildhood strabismus
PACTR201508001241218250
Active, not recruiting
Not Applicable
Behandling med botulinumtoxin vid neurogen blåsfunktionsstörningThe trial addresses patients with severe symptoms of neurogenic detrusor overactivity (urgency and/or urge incontinence). Eligible are those patients who have failed conservative treatment such as behavioral techniques, physiotherapy, intermittent catheterisation or pharmacotherapy.
EUCTR2005-003068-47-SERegion Skåne, Universitetssjukhuset i Lund, Urologiska kliniken40
Completed
Phase 4
Effect of Botulinum Toxin to Hallux Valgus in Addition to Total Contact InsoleHallux Valgus
NCT01501500Chang Gung Memorial Hospital25
Active, not recruiting
Phase 1
How affect the salivary gland treatment with Botulinum neurotoxin type A oral health in patients suffer for drooling?HypersalivationMedDRA version: 18.0Level: LLTClassification code 10020746Term: HypersalivationSystem Organ Class: 100000004856Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]
EUCTR2015-000682-30-EETartu University Hospital90